Pliant Therapeutics director files Form 3

Pliant Therapeutics, Inc. director Robert Iannone filed an initial statement of beneficial ownership on Form 3.

Rhea-AI Filing Summary

Pliant Therapeutics, Inc. director Robert Iannone filed an initial statement of beneficial ownership on Form 3. The structured data shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, or other transactions in this filing.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative exercises: 0 +2 more

5 metrics

Buy transactions 0 buyCount in the transaction summary

Sell transactions 0 sellCount in the transaction summary

Derivative exercises 0 exerciseCount in the transaction summary

Gift transactions 0 giftCount in the transaction summary

Net buy/sell direction neutral netBuySellDirection in the transaction summary

Key Terms

beneficial ownership, reporting person, derivative transactions

3 terms

beneficial ownership regulatory

"filed an initial statement of beneficial ownership on Form 3"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The reporting person is Robert Iannone, identified as a director"

derivative transactions financial

"The Form 3 shows no derivative transactions in the summary"

Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing by Pliant Therapeutics (PLRX) report?

The Form 3 filing reports that director Robert Iannone has filed an initial statement of beneficial ownership. The structured data shows no reported transactions, such as purchases, sales, or option exercises, in this filing.

Does the Pliant Therapeutics (PLRX) Form 3 show any stock purchases or sales?

No, the Form 3 for Pliant Therapeutics shows zero reported buys or sells. The transaction summary lists buyCount 0 and sellCount 0, indicating no open-market purchases or sales in this filing.

Who is the reporting person in the Pliant Therapeutics (PLRX) Form 3?

The reporting person is Robert Iannone, identified as a director of Pliant Therapeutics, Inc. He is not reported as an officer or ten percent owner in the structured filing data.

Are there any derivative transactions in the Pliant Therapeutics (PLRX) Form 3?

No, the Form 3 shows no derivative transactions. The transaction summary reports exerciseCount 0 and derivativeTransactionCount 0, and the derivative holdings section is empty in this filing.

What does the transaction summary indicate in the PLRX Form 3?

The transaction summary indicates no activity: buyCount, sellCount, exerciseCount, giftCount, and taxWithholdingCount are all 0, and netBuySellDirection is reported as neutral for this Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Iannone Robert

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/09/2026

3. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 Power of Attorney

No securities are beneficially owned.

	/s/ Jennifer Woo, attorney-in-fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)